Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.

被引：8
|
作者：
Ozguroglu, Mustafa
Sezer, Ahmet
Kilickap, Saadettin
Gumus, Mahmut
Bondarenko, Igor
Gogishvili, Miranda
Turk, Haci M.
Cicin, Irfan
Bentsion, Dmitry
Gladkov, Oleg
Clingan, Philip R.
Sriuranpong, Virote
Rizvi, Naiyer A.
McGinniss, Jennifer
Pouliot, Jean-Francois
Lee, Sue
Seebach, Frank A.
Lowy, Israel
Gullo, Giuseppe
Rietschel, Petra
机构：
[1] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Istanbul, Turkey
[2] Baskent Univ, Dept Med Oncol, Adana, Turkey
[3] Hacettepe Univ, Inst Canc, Dept Med Oncol, Ankara, Turkey
[4] Istanbul Medeniyet Univ, Sch Med, Dept Med Oncol, Istanbul, Turkey
[5] Dnipropetrovsk Med Acad, Dept Oncol & Med Radiol, Dnipro, Ukraine
[6] Univ Clin Ltd, High Technol Med Ctr, Tbilisi, GA USA
[7] Bezmialem Vakif Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey
[8] Trakya Univ, Dept Med Oncol, Edirne, Turkey
[9] Sverdlovsk Reg Oncol Ctr, Dept Radiotherapy, Ekaterinburg, Russia
[10] LLC EVIMED, Chelyabinsk, Russia
[11] Univ Wollongong, Wollongong Hosp, Illawarra Canc Ctr, Southern Med Day Care Ctr, Wollongong, NSW, Australia
[12] Univ Wollongong, Wollongong Hosp, Illawarra Canc Ctr, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia
[13] Chulalongkorn Univ, Fac Med, Dept Med, Div Med Oncol, Bangkok, Thailand
[14] King Chulalongkorn Mem Hosp, Bangkok, Thailand
[15] Columbia Univ, Med Ctr, Div Hematol Oncol, New York, NY USA
[16] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9085
引用
收藏
页数：3
相关论文
共 50 条
  • [1] EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients ( pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%-3-year update
    Kilickap, S.
    Ozguroglu, M.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O. A.
    Clingan, P.
    Sriuranpong, V.
    He, X.
    Pouliot, J-F.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S42 - S43
  • [2] EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
    Sezer, A.
    Kilickap, S.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Li, S.
    Lee, S.
    Gullo, G.
    Lowy, I.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1388 - S1388
  • [3] EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
    Sezer, A.
    Kilickap, S.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    Turk, H. M.
    Cicin, I.
    Bentsion, D.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Li, S.
    Lee, S.
    Gullo, G.
    Lowy, I.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1182 - S1183
  • [4] BUDGET IMPACT ANALYSIS OF CEMIPLIMAB FOR FIRST-LINE (1L) ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH PROGRAMMED CELL DEATH-LIGAND 1 (PD-L1)≥ 50% IN ITALY
    Rumi, F.
    Xoxi, L.
    Cicchetti, A.
    VALUE IN HEALTH, 2022, 25 (12) : S147 - S147
  • [5] Budget impact (BI) analysis of cemiplimab for first-line (1L) advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% in the United States.
    Kuznik, Andreas
    Smare, Caitlin
    Chen, Chieh-I
    Venkatachalam, Meena
    Keeping, Sam
    Atsou, Kokuvi
    Xu, Yingxin
    Wilson, Florence
    Guyot, Patricia
    Chan, Keith
    Glowienka, Emily
    Konidaris, Gerasimos
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Clinical interchangeability of programmed cell death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays for the treatment of first-line (1L) non-small cell lung cancer (NSCLC) with cemiplimab
    Kerr, K. M.
    Perez, J.
    McGuire, K.
    Baker, B.
    Fang, F.
    Li, J.
    Wlasiuk, G.
    Li, S.
    Gao, B.
    Pouliot, J-F.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S590 - S591
  • [7] Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study
    Gumus, Mahmut
    Chen, Chieh-, I
    Ivanescu, Cristina
    Kilickap, Saadettin
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Harnett, James
    Mastey, Vera
    Naumann, Ulrike
    Reaney, Matthew
    Konidaris, Gerasimos
    Sasane, Medha
    Brady, Keri J. S.
    Li, Siyu
    Gullo, Giuseppe
    Rietschel, Petra
    Sezer, Ahmet
    CANCER, 2023, 129 (01) : 118 - 129
  • [8] BUDGET IMPACT (BI) OF FIRST-LINE (1L) CEMIPLIMAB MONOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) WITH PROGRAMMED CELL DEATH-LIGAND 1 (PD-L1) $50% IN A LARGE US HEALTH PLAN: AN UPDATED ANALYSIS
    Quek, R. G. W.
    Theriou, C.
    Smare, C.
    Keeping, S.
    Xu, Y.
    Konidaris, G.
    LaFontaine, P. R.
    Harnett, J.
    VALUE IN HEALTH, 2022, 25 (07) : S388 - S388
  • [9] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
    Gogishvili, M.
    Melkadze, T.
    Makharadze, T.
    Giorgadze, D.
    Dvorkin, M.
    Penkov, K. D.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    Gessner, C.
    Jaime, B. Moreno
    Passalacqua, R.
    Li, S.
    McGuire, K.
    Quek, R. G.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S1567 - S1568
  • [10] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
    Gogishvili, M.
    Melkadze, T.
    Makharadze, T.
    Giorgadze, D.
    Dvorkin, M.
    Penkov, K. D.
    Laktionov, K.
    Nemsadze, G.
    Nechaeva, M.
    Rozhkova, I.
    Kalinka, E.
    Gessner, C.
    Moreno-Jaime, B.
    Passalacqua, R.
    Li, S.
    McGuire, K.
    Quek, R. G. W.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1328 - S1328
12345